C07C219/08

PREPARATION OF N,N-(DI)ALKYLAMINOALKYL(METH)ACRYLAMIDE OR N,N-(DI)ALKYLAMINOALKYL (METH)ACRYLATE AND THE QUATERNARY AMMONIUM SALTS THEREOF AS FLOCCULATING AIDS AND GELLING AGENTS
20170369424 · 2017-12-28 · ·

N,N-(di)alkylaminoalkyl(meth)acrylamide or N,N-(di)alkylaminoalkyl (meth)acrylate and/or a quaternary ammonium salt thereof are prepared with a low content of a compound of formula (IV)

##STR00001##

wherein R.sub.5 in each case is a linear, branched or cyclic alkyl radical, an aryl radical which may also be substituted by one or more alkyl groups, the linear, cyclic or branched alkyl radical may have a length of 1-12 carbon atoms and is, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, isooctyl, nonyl, decyl, undecyl, dodecyl.

ACYCLIC LIPIDS AND METHODS OF USE THEREOF
20230202966 · 2023-06-29 ·

The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.

ACYCLIC LIPIDS AND METHODS OF USE THEREOF
20230202966 · 2023-06-29 ·

The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.

Cationic lipid

The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) (wherein: R.sup.1 and R.sup.2 are, the same or different, alkenyl, etc, and X.sup.1 and X.sup.3 are hydrogen atoms, or are combined together to form a single bond or alkylene, and X.sup.3 is absent or is alkyl, etc, Y is absent or anion, a and b are, the same or different, 0 to 3, and L.sup.3 is a single bond, etc, R.sup.3 is alkyl, etc, L.sup.1 and L.sup.2 are —O—, —CO—O— or —O—CO—), a composition comprising the cationic lipid and a nucleic acid, and a method for introducing a nucleic acid into a cell by using the composition comprising the cationic lipid and the nucleic acid, and the like. ##STR00001##

Cationic lipid

The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) (wherein: R.sup.1 and R.sup.2 are, the same or different, alkenyl, etc, and X.sup.1 and X.sup.3 are hydrogen atoms, or are combined together to form a single bond or alkylene, and X.sup.3 is absent or is alkyl, etc, Y is absent or anion, a and b are, the same or different, 0 to 3, and L.sup.3 is a single bond, etc, R.sup.3 is alkyl, etc, L.sup.1 and L.sup.2 are —O—, —CO—O— or —O—CO—), a composition comprising the cationic lipid and a nucleic acid, and a method for introducing a nucleic acid into a cell by using the composition comprising the cationic lipid and the nucleic acid, and the like. ##STR00001##

Low Molecular Weight Dry Powder Polymer for Use as Paper-Making Dry Strength Agent

The invention provides an associative polymer, a powder, and a process for making a powder comprising, networking one or more associative polymer(s) and one or more optional surfactant(s) to form a wet gel, and forming a powder from the wet gel, wherein the associative polymer(s) have a weight average molecular weight of from about 10 kDa to about 2,000 kDa.

Low Molecular Weight Dry Powder Polymer for Use as Paper-Making Dry Strength Agent

The invention provides an associative polymer, a powder, and a process for making a powder comprising, networking one or more associative polymer(s) and one or more optional surfactant(s) to form a wet gel, and forming a powder from the wet gel, wherein the associative polymer(s) have a weight average molecular weight of from about 10 kDa to about 2,000 kDa.

Prodrugs of fumarates and their use in treating various diseases

The present invention provides compounds of formula (I), and pharmaceutical compositions thereof. ##STR00001##

Prodrugs of fumarates and their use in treating various diseases

The present invention provides compounds of formula (I), and pharmaceutical compositions thereof. ##STR00001##

Polyamine-fatty acid derived lipidoids and uses thereof

The present disclosure provides polyamine-fatty acid derived lipidoids (e.g., compounds of Formula (I) or (II)) and methods of preparing the lipidoids. A described lipidoid includes R—C(═O)—O— moieties (where R is a lipid moiety), which may be hydrolyzed into non-toxic fatty acids. Also provided are compositions including a described lipidoid and an agent (e.g., polynucleotide, small molecule, peptide, or protein). The present disclosure also provides methods, kits, and uses that involve the lipidoids or compositions for delivering an agent to a subject, tissue, or cell and/or for treating and/or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, immunological diseases, gastrointestinal diseases, respiratory diseases, painful conditions, psychiatric disorders, and metabolic disorders. ##STR00001##